BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LX1001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LX1001\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05400330-698@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:LX1001: Phase 1 readout est. (NCT05400330)
DESCRIPTION:LX1001\, phase 1\, Alzheimer's Disease.\nStudy: Long-Term Follo
 w-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease\nEstimated p
 rimary completion: November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lx1001#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05400330
URL:https://assetmemo.bio/drug/lx1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
